Shifting sands of EU politics make pro-industry concessions likely

As European drugmakers wrestle with regional lawmakers over  proposed legislative changes, the industry has been emboldened by a German government report raising substantial concerns.

The political landscape has also shifted, following the collapse of the ruling coalition in the Netherlands, potentially bringing to an end a pro-reform alliance in favor of the legislation.

Led by The European Federation of Pharmaceutical Industries and Associations (EFPIA), drugmakers have taken a  strong stance against the new laws, which include shortening the period of exclusivity granted for novel medicines.